Luoxin picks up NSCLC candidate from Yuhan

Yuhan Corp. (KSE:000100) granted Shandong Luoxin Pharmaceutical Group Stock Co. Ltd. (HKSE:8058) exclusive rights to EGFR-mutation positive non-small cell lung cancer candidate YH25448 in Greater China, including mainland China, Hong Kong and Macau.

The partners said they will develop YH25448 simultaneously in Asian territories, and aim for concurrent NDA submissions. Yuhan is to conduct clinical development in South Korea and Taiwan, while Luoxin will develop the candidate in Greater China. Yuhan said it is eligible for $120 million in total milestones, plus double-digit royalties. Director and Head of R&D Strategy and Partnering Han-Joo Kim told BioCentury that Yuhan received $6 million up front. ...